A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC 761968 IND 116059) VERSUS WEEKLY PACLITAXEL (NSC 673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Trial Profile

A RANDOMIZED PHASE II STUDY OF NCI SUPPLIED CABOZANTINIB (NSC 761968 IND 116059) VERSUS WEEKLY PACLITAXEL (NSC 673089) IN THE TREATMENT OF PERSISTENT OR RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Cabozantinib (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2017 Planned primary completion date changed from 15 Aug 2016 to 1 Oct 2018.
    • 10 Jun 2017 Biomarkers information updated
    • 30 Apr 2015 Primary endpoint (Progression-free survival) has not been met, according to Exelixis first quarter 2015 financial report.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top